Tuoxin Pharmaceutical announced that Tuoxin Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently obtained a “Pharmaceutical Production License” issued by the Hainan Drug Administration. The license number is Qiong 20260194, which is valid until November 2, 2031. The production scope is tablets and capsules. The supporting production line covers the production site conditions for etoglizine tablets, dortinolide tablets, etc. The acquisition of this qualification indicates that the subsidiary's solid preparation workshop has the corresponding production qualification conditions, and is an important step forward in the company's extension to the formulation industry chain. Currently, the above formulations have not obtained drug registration approval numbers, and there is uncertainty about whether they can be successfully approved and commercialized.

Tuoxin Pharmaceutical announced that Tuoxin Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently obtained a “Pharmaceutical Production License” issued by the Hainan Drug Administration. The license number is Qiong 20260194, which is valid until November 2, 2031. The production scope is tablets and capsules. The supporting production line covers the production site conditions for etoglizine tablets, dortinolide tablets, etc. The acquisition of this qualification indicates that the subsidiary's solid preparation workshop has the corresponding production qualification conditions, and is an important step forward in the company's extension to the formulation industry chain. Currently, the above formulations have not obtained drug registration approval numbers, and there is uncertainty about whether they can be successfully approved and commercialized.